Diabetes Increases Cancer Risk by Up to 20%
Diabetes Increases Cancer Risk by Up to 20%
See this week's Item #1.
CAD Risk for Pre-Diabetes Comparable to Diabetes
CAD Risk for Pre-Diabetes Comparable to Diabetes
See this week's Item #3.
AACE Establishes New Treatment Guidelines for the Treatment of Diabetes and Prediabetes
AACE Establishes New Treatment Guidelines for the Treatment of Diabetes and Prediabetes
See this week's Item #1.
FreeStyle® InsuLinx Glucose Meter Recall
FreeStyle® InsuLinx Glucose Meter Recall
Abbott has issued a recall for the FreeStyle InsuLinx Blood Glucose Meters in the United States to address the potential for an inaccurate reading at rare, extremely high blood...
FDA Approves Johnson & Johnson’s First In Class SGLT-2 Inhibitor Diabetes Drug, Canagliflozin
FDA Approves Johnson & Johnson’s First In Class SGLT-2 Inhibitor diabetes drug, canagliflozin (Invokana). See this...
Lixisenatide (Lyxumia) has been accepted for review by the FDA.
Lixisenatide (Lyxumia) has been accepted for review by the FDA.
French drugmaker Sanofi said on Tuesday that its experimental GLP-1 once-daily diabetes drug lixisenatide (Lyxumia) has been accepted for review by the FDA. Sanofi is...
J&J buys Calibre Medical, maker of the Finesse Insulin Patch
J&J buys Calibre Medical, maker of the Finesse Insulin Patch. See the Product of the...
January 19, 2013
FDA Advisory Committee Recommends Approval of First in Class SGLT-2(Canagliflozin).
Next Once Weekly GLP-1 (albiglutide) Submitted to FDA for Approval.
First SGLT-2 First-in-Class Drug to Treat Diabetes Under Scrutiny
First SGLT-2 First-in-Class Drug to Treat Diabetes Under Scrutiny
See this week's Item #3.
ADA Releases New Standards of Medical Care for 2013
ADA Releases New Standards of Medical Care for 2013
See this week's Item #2.
